Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Severe Combined Immunodeficiency 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 53Etoposide 33Temozolomide 28Irinotecan 28Melphalan 25Filgrastim 25Topotecan 24Carboplatin 243-Iodobenzylguanidine 23Isotretinoin 20Granulocyte Colony-Stimulating Factor 17sargramostim 16humanized 3F8 anti-GD2 monoclonal antibody 16dinutuximab 16Granulocyte-Macrophage Colony-Stimulating Factor 16fludarabine 15Vincristine 15Doxorubicin 15Cisplatin 15Peripheral Blood Stem Cell Transplantation 14Interleukin-2 14Busulfan 13naxitamab 12Thiotepa 12Radiotherapy 12aldesleukin 11fludarabine phosphate 10etoposide phosphate 8Mesna 8Ifosfamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroblastoma × Prospective Studies × Clear all
NCT00695279 2024-10-30

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

St. Jude Children's Research Hospital

Completed
41 enrolled
CNSOther hematologic neoplasm

Mucopolysaccharidosis I, Neoplasms, Neuroblastoma, Severe Combined Immunodeficiency, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡